RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M

RenovoRx, Inc.

2026-Q1 EPS reported -$0.09 revenue$563,000

Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.
Net loss $3.5M vs $2.4M a year ago; cash $12.4M with runway into H2 2027.
Active commercial cancer centers grew to 16 from 8 at year-end 2025; target 36 by year-end 2026.
Phase III TIGeR-PaC enrollment at 106 of 114 patients (93%); full enrollment expected by June 2026.
FY 2026 revenue guidance reaffirmed at $3-4 million.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.